1. The latest on the AbbVie-Allergan tie-up — Patience needed for US biosimilar market — Medtech salary survey data — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Pain Space

Discussion in 'BioDelivery Sciences' started by anonymous, Mar 29, 2018 at 11:59 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I'm so tired of selling in pain market! So much negative commentary! Even more tired of my manager for telling me how great of an opportunity this is for me here! Not sure if I should start looking?
     

  2. anonymous

    anonymous Guest

    No reason to look-sales are very strong for this dud.
     
  3. anonymous

    anonymous Guest

    Yes sales are good and not currently looking! Just tired of the song and dance!
     
  4. anonymous

    anonymous Guest

    Stick out for at least a year, then begin looking. The Pain space is a pain. Agreed!
     
  5. anonymous

    anonymous Guest

    Total net revenue for BELBUCA (buprenorphine) buccal film and BUNAVAIL® (buprenorphine and naloxone) buccal film in the fourth quarter was $9.4 million and $1.7 million, respectively, versus $6.4 million and $1.7 million, in the third quarter of 2017.